Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Serina Therapeutics, Inc. incurred convertible notes of $10,000,000 with Juvenescence Limited at origination fee in an amount equal to 7% of the loan funds disbursed to AgeX maturing March 13, 2026.
- Instrument
- convertible notes
- Principal
- $10,000,000
- Counterparty
- Juvenescence Limited
- Rate
- origination fee in an amount equal to 7% of the loan funds disbursed to AgeX
- Maturity
- March 13, 2026
- Event
- incurrence
Exact text from the filing
(“ AgeX ”) and Juvenescence Limited (“ Juvenescence ”) entered into a Secured Convertible Promissory Note (the “ Juvenescence Note ”) pursuant to which Juvenescence
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Michael D. West resigned as Director at Serina Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On March 9, 2023, Dr. Michael D. West resigned from AgeX’s Board.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. entered into Convertible Note Purchase Agreement with AgeX Therapeutics, Inc. valued at $10,000,000 (effective 2023-03-15).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- AgeX Therapeutics, Inc.
- Value
- $10,000,000
- Effective
- 2023-03-15
Exact text from the filing
Serina Therapeutics Inc., an Alabama corporation (“ Serina ”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement, dated March 15, 2023 (the “ Serina Note Purchase Agreement ”), between AgeX and Serina.
View on SEC.gov